Stem cell therapy for lung disease in scleroderma
Treatments studied
Part of Immune system & allergy, Lungs & breathing clinical trials.
This trial tests whether a special type of stem cells from umbilical cords can help people with scleroderma-related lung disease that is getting worse. You may qualify if your lung function has declined despite current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old
- You have scleroderma with lung scarring seen on a CT scan
- Your lung function has worsened in the last 2 years despite treatment
- You can walk for 6 minutes and do breathing tests
- You do not have other serious lung conditions or recent infections
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-stage trial tests a new treatment using extracts from human umbilical cord stem cells, given by inhalation, to see if it is safe and can help patients with interstitial lung disease (a condition where lung tissue becomes scarred and stiff). The study will measure whether this approach reduces symptoms and improves how well your lungs work.
This trial tests a new CAR-T cell therapy called relmacabtagene autoleucel for people with diffuse systemic sclerosis (scleroderma) that is not responding to standard treatments. The goal is to see if this therapy can help control the disease.
This trial tests new treatments for people with scleroderma-related lung disease. You may be eligible if you have systemic sclerosis with lung scarring, your symptoms started within the last 7 years, and you have not had certain prior treatments or transplants.
This trial tests whether combining two drugs, rituximab and mycophenolate mofetil, is safe and works better than standard care for lung scarring caused by scleroderma. It may be an option if your lung disease is severe or getting worse.
This study tests whether a combination of two drugs, nintedanib and tocilizumab, can help people with systemic sclerosis (a condition that causes skin and organ hardening) who also have lung scarring (interstitial lung disease). The goal is to find a treatment that can slow down the disease.
This trial tests whether infusions of donor stem cells from fat tissue can help people with severe systemic sclerosis (a serious autoimmune disease that hardens the skin and can affect internal organs). It is for patients who haven't improved with other treatments or cannot undergo a standard stem cell transplant.
Hear when a new CTD-ILD trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.